secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001323885-24-000115
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M
--------------------------------------------------------------------------------

- Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).
- Net loss per share $0.17 vs $0.20 YoY; adjusted EBITDA $7.9M, up $3.2M from Q3 2023.
- Gross margin 74.9%, down 27 bps YoY due to unfavorable product/geographic mix.
- Generated $16.3M cash flow from operations in the quarter.
- Launched new products; growth driven by open ablation, appendage management, and pain management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000115/0001323885-24-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000115/atrc-20241029.htm
  HTML page:      https://secwatch.observer/filing/0001323885-24-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer